Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Replimune Group Inc (REPL)
NASDAQ:REPL
Replimune Group (REPL) Stock Price & Analysis
216 Followers
REPL Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.92 - $22.21
Previous Close$8.09
Volume336.04K
Average Volume (3M)1.22M
Market Cap
$496.85M
Enterprise Value$152.05M
Total Cash (Recent Filing)$420.67M
Total Debt (Recent Filing)$75.87M
Price to Earnings (P/E)―
Beta0.76
Next Earnings
Aug 01, 2024EPS Estimate
-$0.86Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.31
Shares Outstanding61,415,105
10 Day Avg. Volume2,829,737
30 Day Avg. Volume1,224,258
Standard Deviation0.22
R-Squared0.07
Alpha-0.00891
Financial Highlights & Ratios
Price to Book (P/B)1.24
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-1.00
Forecast
1Y Price Target
$14.50Price Target Upside78.79% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Replimune Group News
PremiumCompany Announcements
Replimune Group Secures Funding for Cancer Treatment Expansion
PremiumCompany Announcements
Replimune Group’s IGNYTE Trial Shows Promising Melanoma OutcomesBulls Say, Bears Say
Bulls Say
Clinical DataREPL presented positive RP1 data from the primary analysis of the IGNYTE cohort by independent central review.
FinancialsReplimune ended F4Q24 with ~$420.7M in cash, cash equivalents, and marketable securities, extending the operational runway into calendar 2H26.
Regulatory PathResults support potential accelerated approval of RP1 + Opdivo in anti-PD1 failed melanoma patients, with an expected BLA submission.
Bears Say
EarningsReplimune recorded a net loss of $0.83 per share, modestly wider than the estimated net loss of $0.74 per share.
Financial PerformanceThe CERPASS failure last year is a setback.
Financial PerformanceThe failure of RP1 in the CERPASS study on primary response-based endpoints in CSCC is considered a setback.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
REPL FAQ
What was Replimune Group Inc’s price range in the past 12 months?
Replimune Group Inc lowest stock price was $4.92 and its highest was $22.21 in the past 12 months.
What is Replimune Group Inc’s market cap?
Currently, no data Available
When is Replimune Group Inc’s upcoming earnings report date?
Replimune Group Inc’s upcoming earnings report date is Aug 01, 2024 which is in 26 days.
How were Replimune Group Inc’s earnings last quarter?
Replimune Group Inc released its earnings results on May 16, 2024. The company reported -$0.82 earnings per share for the quarter, missing the consensus estimate of -$0.768 by -$0.052.
Is Replimune Group Inc overvalued?
According to Wall Street analysts Replimune Group Inc’s price is currently Undervalued.
Does Replimune Group Inc pay dividends?
Replimune Group Inc does not currently pay dividends.
What is Replimune Group Inc’s EPS estimate?
Replimune Group Inc’s EPS estimate is -$0.86.
How many shares outstanding does Replimune Group Inc have?
Replimune Group Inc has 61,415,104 shares outstanding.
What happened to Replimune Group Inc’s price movement after its last earnings report?
Replimune Group Inc reported an EPS of -$0.82 in its last earnings report, missing expectations of -$0.768. Following the earnings report the stock price went down -1.322%.
Which hedge fund is a major shareholder of Replimune Group Inc?
Among the largest hedge funds holding Replimune Group Inc’s share is Baker Bros Advisors LP. It holds Replimune Group Inc’s shares valued at 78M.
---
Replimune Group Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.50 (78.79% Upside)
$14.50 (78.79% Upside)
Blogger Sentiment
Bullish
REPL Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 979.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $634.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.6%
Last 30 Days ▲ 0.5%
Last 30 Days ▲ 0.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-63.09%
12-Months-Change
Fundamentals
Return on Equity
-46.42%
Trailing 12-Months
Asset Growth
-24.57%
Trailing 12-Months
Company Description
Replimune Group Inc
Replimune Group, Inc. is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. Oncolytic immunotherapy is a cancer treatment that exploits the ability of certain viruses to selectively replicate in an direct kill turmors, as well as induce a potent, patient-specific, anti-tumor immune response. The company was founded by Philip Astley-Sparke, Colin Love and Robert Coffin in March 2015 and is headquartered in Woburn, MA.
---
REPL Stock 12 Month Forecast
Average Price Target
$14.50
▲(78.79% Upside)
Technical Analysis
Best Analysts Covering REPL
1 Year
1 Year Success Rate
7/13 ratings generated profit
1 Year Average Return
-5.33%
reiterated a buy rating 30 days ago
Copying Peter Lawson's trades and holding each position for 1 Year would result in 53.85% of your transactions generating a profit, with an average return of -5.33% per trade.
---